Blog

The abstract submission deadline for the upcoming AHES annual conference in Adelaide on 24-26 September is fast approaching.

This year short presentations ...

[:content [\A \l \e \x \i \o \n \space \P \h \a \r \m \a \space \U \K \space \h \a \s \  \a \n \n \o \u \n \c \e \d \space \t \h \a \t \space \S \o \l \i \r \i \s \  \( \e \c \u \l \i \z \u \m \a \b \) \space \i \s \space \n \o \w \space \c \o \m \m \i \s \s \i \o \n \e \d \space \b \y \space \N \H \S \space \E \n \g \l \a \n \d \space \f \o \r \space \t \h \e \space \t \r \e \a \t \m \e \n \t \space \o \f \space \c \h \i \l \d \r \e \n \space \a \n \d \space \a \d \u \l \t \s \space \w \i \t \h " ..."]]

Amendments to the National Health (Pharmaceutical Benefits) (Conditions of approval for approved pharmacists) Determination 2007 are effective from 1 December 2014.  ...

http://http//www.pharmadispatch.com/michael-wonder-of-maestro-database-breaks-down-the-july-pbac-agenda/ ...

PHARMAC is seeking feedback on a provisional agreement with Apotex NZ Limited, for diltiazem hydrochloride (Apo-Diltiazem CD) long-acting capsules 120 ...

The pCODR Expert Review Committee (pERC) has recommended against the funding of ofatumumab acetate (Arzerra) when used in combination with chlorambucil ...

On the 9 February, the Transparency Commission of the French National Authority for Health published its advice on Zonegran (zonisamide) in its ...

In final draft guidance, NICE says vedolizumab (also called Entyvio, Millennium Pharmaceuticals) can be considered as an option to treat people with ...

NICE has issued final draft guidance proposing to recommend imatinib mesylate, also known as Glivec and made by Novartis, for up to ...

Consumers are the big winners from the Senate today passing the Abbott Government’s Pharmaceutical Benefits Scheme (PBS) reform package, which ...

The National Institute for Health and Care Excellence has not recommended funding the use of Celgene’s Otezla on the National ...

An out-of-session meeting was held on 25 August 2014 to discuss the PBS listing of eculizumab (Soliris) for patients with atypical ...

In draft guidance published today NICE has not recommended abiraterone for prostate cancer which has spread in people whose first treatment has ...

PHARMAC is seeking feedback on a proposal, resulting from a provisional agreement with Janssen-Cilag Pty Ltd, to award Sole Subsidised Supply ...